Table 2 COVID characteristics of the study population between 2020/03 and 2023/08 and clusters.
Characteristics | Cohort (n = 318) | Clusters | ||||
|---|---|---|---|---|---|---|
1 (n = 138) | 2 (n = 42) | 3 (n = 11) | 4 (n = 51) | 5 n = 76) | ||
COVID severity | ||||||
Mild | 299 (94.0%) | 123 (89.1%) | 4- (95.2%) | 11 (100%) | 51 (100%) | 74 (97.4%) |
Moderate | 11 (3.5%) | 11 (8.0%) | - (0%) | - (0%) | - (0%) | - (0%) |
Severe | 8 (2.5%) | 4 (2.9%) | 2 (4.8%) | - (0%) | - (0%) | 2 (2.6%) |
Death | - (0%) | - (0%) | - (0%) | - (0%) | - (0%) | - (0%) |
Infection’s wave | ||||||
1 | 22 (6.9%) | 16 (11.6%) | 6 (14.3%) | - (0%) | - (0%) | - (0%) |
2 | 13- (40.9%) | 11- (79.7%) | 15 (35.7%) | 5 (45.5%) | - (0%) | - (0%) |
3 | 22 (6.9%) | 11 (8.0%) | 7 (16.7%) | 4 (36.4%) | - (0%) | - (0%) |
4 | 26 (8.2%) | 1 (0.7%) | 7 (16.7%) | 1 (9.1%) | 16 (31.4%) | 1 (1.3%) |
5 | 56 (17.6%) | - (0%) | 3 (7.1%) | 1 (9.1%) | 3- (58.8%) | 22 (28.9%) |
6 | 16 (5.0%) | - (0%) | 1 (2.4%) | - (0%) | 2 (3.9%) | 13 (17.1%) |
7 | 46 (14.5%) | - (0%) | 3 (7.1%) | - (0%) | 3 (5.9%) | 4- (52.6%) |
Reinfection’s wave | ||||||
1 | - (0%) | - (0%) | - (0%) | - (0%) | - (0%) | - (0%) |
2 | - (0%) | - (0%) | - (0%) | - (0%) | - (0%) | - (0%) |
3 | - (0%) | - (0%) | - (0%) | - (0%) | - (0%) | - (0%) |
4 | 1 (0.3%) | 1 (0.7%) | - (0%) | - (0%) | - (0%) | - (0%) |
5 | 72 (22.6%) | 45 (32.6%) | 19 (45.2%) | 5 (45.5%) | 3 (5.9%) | - (0%) |
6 | 43 (13.5%) | 32 (23.2%) | 7 (16.7%) | - (0%) | 4 (7.8%) | - (0%) |
7 | 202 (63.5%) | 6- (43.5%) | 16 (38.1%) | 6 (54.5%) | 44 (86.3%) | 76 (100%) |
Delay between events (days): mean (SD) | ||||||
Vaccine1-Vaccine2 | 103 (63.6) | 110 (70.5) | 387 (43.8) | 129 (84.5) | 78.5 (24.3) | 90.3 (23.9) |
Vaccine1-Vaccine3 | 298 (67.8) | 290 (76.4) | – | 331 (66.6) | 331 (77.4) | 293 (49.0) |
Vaccine1-Infection | 70.7 (267) | -151 (91.9) | -173 (118) | 49.5 (70.8) | 255 (81.0) | 416 (83.5) |
Vaccine1-Reinfection | 463 (172) | 379 (114) | 247 (141) | 405 (108) | 518 (123) | 648 (112) |
Vaccine1-Reinfection2 | 523 (151) | 494 (90.9) | 413 (114) | – | – | 747 (177) |
Vaccine1-Reinfection3 | 583 (113) | 553 (133) | – | – | – | 643 (21.9) |
Vaccine2-Vaccine3 | 202 (60.1) | 189 (67.5) | – | 199 (65.1) | 260 (71.6) | 202 (32.0) |
Vaccine2-Infection | -18.6 (285) | -261 (103) | -666 (163) | -79.1 (34.2) | 177 (72.5) | 326 (72.3) |
Vaccine2-Reinfection | 373 (182) | 268 (121) | -213 (125) | 277 (124) | 439 (121) | 557 (102) |
Vaccine2-Reinfection2 | 407 (190) | 371 (107) | -100 (–) | – | – | 656 (150) |
Vaccine2-Reinfection3 | 467 (101) | 410 (62.7) | – | – | – | 581 (18.4) |
Vaccine3-Infection | -169 (269) | -427 (103) | – | -278 (74.4) | -96.0 (45.8) | 125 (62.7) |
Vaccine3-Reinfection | 213 (166) | 111 (134) | – | 88.7 (129) | 179 (129) | 357 (93.6) |
Vaccine3-Reinfection2 | 245 (169) | 171 (98.0) | – | – | – | 486 (111) |
Vaccine3-Reinfection3 | 315 (92.1) | 275 (84.9) | – | – | – | 396 (NA) |
Infection-Reinfection | 391 (177) | 529 (118) | 392 (183) | 356(126) | 263 (103) | 232 (84.2) |
Infection-Reinfection2 | 564 (154) | 614 (107) | 593 (178) | – | – | 330 (48.0) |
Infection-Reinfection3 | 583 (170) | 686 (75.2) | – | – | – | 376 (7.07) |
Reinfection-Reinfection2 | 175 (86.7) | 162 (88.5) | 250 (59.3) | – | – | 139 (61.4) |
Reinfection-Reinfection3 | 210 (69.6) | 222 (78.4) | – | – | – | 186 (62.9) |
Reinfection2-Reinfection3 | 96.5 (69.6) | 102 (88.4) | – | – | – | 85.5 (19.1) |
Doses of vaccine at primary infection: mean (SD) | 1.08 (1.30) | - (0) | 0.024 (0.154) | 1 (0) | 2.02 (0.140) | 2.99 (0.115) |
Doses of vaccine at first reinfection: mean (SD) | 2.36 (0.876) | 2.55 (0.514) | 0.50 (0.506) | 2.64(0.505) | 2.39 (0.493) | 2.99 (0.115) |
Doses of vaccine at second reinfection: mean (SD) | 2.29 (0.864) | 2.60 (0.503) | 0.83 (0.408) | – | – | 2.80 (0.447) |
Doses of vaccine at third reinfection: mean (SD) | 2.50 (0.548) | 2.50 (0.577) | – | – | – | 2.50 (0.707) |
Number of reinfections: mean (SD) | 1.12 (0.375) | 1.17 (0.451) | 1.14 (0.354) | 1.00 (0) | 1.00 (0) | 1.09 (0.372) |
